Elicio Therapeutics Inc. (ELTX) - Total Liabilities
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has total liabilities worth $24.23 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Elicio Therapeutics Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See ELTX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Elicio Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Elicio Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SANUWAVE Health, Inc. Common Stock
NASDAQ:SNWV
|
USA | $35.26 Million |
|
Credit Clear Ltd
AU:CCR
|
Australia | AU$21.08 Million |
|
Bathurst Resources Ltd
F:B0R
|
Germany | €23.69 Million |
|
Formosa Electronic Industries
TWO:8171
|
Taiwan | NT$1.06 Billion |
|
DASAN Networks Inc
KQ:039560
|
Korea | ₩273.81 Billion |
|
Libertas 7 SA
MC:LIB
|
Spain | €65.34 Million |
|
Rein Therapeutics Inc
NASDAQ:RNTX
|
USA | $14.70 Million |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
USA | $416.00K |
Liability Composition Analysis (2012–2025)
This chart breaks down Elicio Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ELTX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 14.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elicio Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual total liabilities of Elicio Therapeutics Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $24.23 Million | -38.65% |
| 2024-12-31 | $39.49 Million | +150.36% |
| 2023-12-31 | $15.77 Million | +14.72% |
| 2022-12-31 | $13.75 Million | -8.38% |
| 2021-12-31 | $15.01 Million | -89.11% |
| 2020-12-31 | $137.80 Million | +352.21% |
| 2019-12-31 | $30.47 Million | +294.87% |
| 2018-12-31 | $7.72 Million | +16.87% |
| 2013-12-31 | $6.60 Million | -2.78% |
| 2012-12-31 | $6.79 Million | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more